Bavarian Nordic Reports Data from a Phase 3 Clinical Trial of its VLP-Based Chikungunya Virus Vaccine in Adults ≥65 Years of Age - Seite 2
About chikungunya virus
Chikungunya is a mosquito-borne viral disease caused by the chikungunya virus (CHIKV). CHIKV disease typically presents with acute symptoms, including fever, rash, fatigue, headache, and often
severe and incapacitating joint pain. While mortality is low, morbidity is high; nearly 50% of individuals with CHIKV disease have debilitating long-term symptoms that can intensify with age. In
the past 20 years, the CHIKV has emerged in several previously non-endemic regions in Asia, Africa, southern Europe, and the Americas, often causing large unpredictable outbreaks. No effective
treatments or vaccines are currently available1.
About the chikungunya vaccine candidate CHIKV VLP
CHIKV VLP (PXVX0317) is an adjuvanted VLP-based vaccine in clinical development for active immunization against chikungunya disease, which is currently being evaluated in two pivotal Phase 3
trials: a multi-center, randomized, double blind, placebo-controlled study to evaluate the safety and immunogenicity of CHIKV VLP in over 3,000 healthy individuals aged 12 to 64 years of age, and a
randomized, double-blind, placebo-controlled study to evaluate the safety and immunogenicity of CHIKV VLP in 413 healthy adults ≥65 years of age.
CHIKV VLP has received Breakthrough Therapy designation and Fast Track designation from the FDA, and PRIME designation from EMA.
About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the research and development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox and
mpox vaccines, which have been developed through our long-standing partnership with the U.S. Government to enhance the public health preparedness and have a strong portfolio of vaccines for
travelers and endemic diseases. Using our live virus vaccine platform technology, MVA-BN and in-licensed technologies, we have created a diverse portfolio of proprietary and partnered product
candidates designed to save and improve lives by unlocking the power of the immune system. For more information visit www.bavarian-nordic.com.
Lesen Sie auch
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ
materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or
other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may
accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made,
except as required by law.